2003; Kikuchi et al., 2006) The serine/threonine kinase GSK-3β has been shown to be involved in several signalling pathways and to regulate several physiological responses, including protein ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

The newly identified glycogen synthase kinase 3β (GSK-3β) substrates 4 that are phosphorylated ... although to further dissect the signaling pathways involved, it will be necessary to apply ...

9-ING-41 is designed to bind to GSK-3β, disrupting cancer pathways associated with the invasion of tumor cells and resistance to chemotherapeutic agents and radiation. In preclinical tests ...

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy. This is an ASCO Meeting Abstract from the 2019 Genitourinary Cancers Symposium.

In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ATP-competitive pyrrolo[2,3-b]pyridine-based glycogen synthase kinase 3β (GSK-3β) ...

4M Therapeutics Inc. has announced the presentation of preclinical data on its small-molecule glycogen synthase kinase-3β (GSK-3β) inhibitors in models of bipolar disorder. Preclinical data support 4M ...